INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $71,355,434 | -6.0% | 1,369,849 | +14.3% | 3.86% | -5.0% |
| Q2 2023 | $75,918,844 | +16.9% | 1,198,971 | 0.0% | 4.06% | +48.0% |
| Q1 2023 | $64,924,280 | +18.3% | 1,198,971 | +15.6% | 2.74% | +19.0% |
| Q4 2022 | $54,875,288 | +38.4% | 1,036,948 | +21.7% | 2.30% | +40.0% |
| Q3 2022 | $39,642,000 | -48.1% | 851,958 | -36.4% | 1.65% | -43.4% |
| Q2 2022 | $76,413,000 | -18.5% | 1,338,700 | -12.6% | 2.91% | +1.5% |
| Q1 2022 | $93,738,000 | +43.1% | 1,531,923 | +22.4% | 2.86% | +125.6% |
| Q4 2021 | $65,527,000 | +40.4% | 1,251,946 | 0.0% | 1.27% | +61.5% |
| Q3 2021 | $46,673,000 | +10.1% | 1,251,946 | +20.5% | 0.79% | +24.0% |
| Q2 2021 | $42,403,000 | +20.3% | 1,038,770 | 0.0% | 0.63% | +21.7% |
| Q1 2021 | $35,245,000 | +22.3% | 1,038,770 | +14.7% | 0.52% | +26.8% |
| Q4 2020 | $28,810,000 | +128.1% | 905,970 | +84.0% | 0.41% | +80.3% |
| Q3 2020 | $12,632,000 | – | 492,270 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |